Edwards Lifesciences Corporatio found using ticker (EW) now have 22 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The range between the high target price and low target price is between 128 and 73 with the average target price sitting at 94.27. Now with the previous closing price of 74.1 this would imply there is a potential upside of 27.2%. The 50 day MA is 80.89 and the 200 day MA is 97.79. The market cap for the company is $45,943m. Company Website: https://www.edwards.com
The potential market cap would be $58,449m based on the market concensus.
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient’s heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
